News

Biopharma news, November 13, 2026

The most important drug and company news of November 13, 2026, ranked, each linked to its Gosset profiles.

  1. Approval

    Mexico Approves Restylane Shaype

    Mexico approved Restylane Shaype for temporary chin augmentation and jawline definition, marking its first jawline approval worldwide. Galderma anticipates a Mexican launch in the first half of 2027. The company cited chin and jawline studies showing improvements in definition and patient satisfaction.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  2. Pivotal readout

    Positive EU Opinion for WELIREG

    The EMA's CHMP recommended approval of WELIREG plus lenvatinib for adults with advanced clear cell renal cell carcinoma following PD-1 or PD-L1 inhibitor treatment. The European Commission decision remains pending. In the Phase 3 LITESPARK-011 trial, the combination reduced the risk of progression or death by 26% versus cabozantinib; final overall survival results did not meet statistical significance. Serious adverse reactions occurred in 54% of combination-treated patients. Key risks included anemia, hypoxia, cardiac dysfunction and embryo-fetal toxicity.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  3. M&A

    Tong Ren Tang Plans Acquisition

    Beijing Tong Ren Tang proposes to acquire 60% of Tianjin Tong Ren Tang Group from its controlling shareholder for RMB 2.4438 billion in cash. The board approved the related-party transaction, which remains subject to shareholder approval. Payment will be made in two installments, with interest and a guarantee required for the second installment. The target's hospital-focused products and distribution channels are expected to complement the buyer's retail business, although policy, competition and earnings-volatility risks remain.

    Source types: SEC/exchange filing. Sources are available to Gosset users. Log in to see them.

  4. Pivotal readout

    Arrowhead Reports Fiscal 2026 Results

    Fiscal 2026 revenue fell to $450.8 million from $829.4 million, while Arrowhead's net loss widened to $724.2 million; year-end cash resources were $1.193 billion. REDEMPLO prescriptions grew and Arrowhead submitted an FDA supplemental application for severe hypertriglyceridemia after positive Phase 3 results; a potential U.S. launch is planned for the second quarter of 2027, subject to approval. Arrowhead reported interim ARO-DIMER-PA and ARO-MAPT data, completed enrollment in the Phase 3 YOSEMITE trial of zodasiran, and refinanced its credit facility.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  5. Approval

    Sinovent Drug Approved

    The headline reports approval of Sinovent's Yaminxifu for Injection. The product is described as a Class 1 innovative drug. The supplied body contains images but no readable article text, so the indication and approval details cannot be verified.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call